InspireMD's CGuard Carotid EPS Approved in Australia

 

November 28, 2018—InspireMD, Inc. announced that Australia's Therapeutic Goods Administration approved the CGuard embolic prevention system (EPS) for the prevention of stroke caused by the treatment of carotid artery disease. The device is approved for commercial sale and reimbursement and will be launched in Australia immediately in collaboration with InspireMD’s local distribution partner, Diverse Devices Pty Ltd., of Sydney.

In 2013, InspireMD received European CE Mark approval for the self-expanding nitinol CGuard carotid EPS, which is based on the company’s MicroNet mesh protection platform technology that is also used for the treatment of myocardial infarction patients in InspireMD’s commercially available coronary MGuard and MGuard Prime EPS devices.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.